Small molecule immuno-oncology therapeutic agents.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Cancer immunotherapy, activating antitumor immune responses, is a standard therapy.
• Current antibody-based immunotherapies show limited efficacy in a significant patient proportion, highlighting an unmet need.
• Small molecule immuno-oncology agents are emerging as a promising alternative to antibody therapies.

Purpose of the Study:

• To provide an overview of various small molecule approaches in immuno-oncology.
• To discuss modulators of established targets like programmed cell death 1 (PD-1).
• To explore novel, yet-to-be-clinically validated small molecule strategies.

Main Methods:

• Literature review and perspective synthesis.
• Analysis of small molecule immuno-oncology agents.
• Discussion of target modulation, including PD-1 and novel targets.

Main Results:

• Small molecule immuno-oncology agents represent a rapidly developing field.
• These agents target both validated pathways (e.g., PD-1) and novel mechanisms.
• A range of small molecule strategies are under investigation for cancer treatment.

Conclusions:

• Small molecules are a significant and growing area in immuno-oncology development.
• Further clinical validation is required for novel small molecule approaches.
• These agents hold potential to address the unmet need in non-responsive cancer patients.